Cardiovascular Systems (NASDAQ: APOP) and CELLECT BIOTECH/S (NASDAQ:APOP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

85.2% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 3.7% of CELLECT BIOTECH/S shares are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Cardiovascular Systems and CELLECT BIOTECH/S, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiovascular Systems 0 4 4 0 2.50
CELLECT BIOTECH/S 0 0 1 0 3.00

Cardiovascular Systems currently has a consensus target price of $37.00, suggesting a potential downside of 3.85%. CELLECT BIOTECH/S has a consensus target price of $14.00, suggesting a potential upside of 177.23%. Given CELLECT BIOTECH/S’s stronger consensus rating and higher possible upside, analysts plainly believe CELLECT BIOTECH/S is more favorable than Cardiovascular Systems.

Profitability

This table compares Cardiovascular Systems and CELLECT BIOTECH/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardiovascular Systems 0.79% 1.36% 0.88%
CELLECT BIOTECH/S N/A -93.06% -60.94%

Valuation & Earnings

This table compares Cardiovascular Systems and CELLECT BIOTECH/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardiovascular Systems $217.04 million 5.94 $1.71 million $0.05 769.60
CELLECT BIOTECH/S N/A N/A -$8.14 million ($1.46) -3.46

Cardiovascular Systems has higher revenue and earnings than CELLECT BIOTECH/S. CELLECT BIOTECH/S is trading at a lower price-to-earnings ratio than Cardiovascular Systems, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Comparatively, CELLECT BIOTECH/S has a beta of 3.6, meaning that its stock price is 260% more volatile than the S&P 500.

Summary

Cardiovascular Systems beats CELLECT BIOTECH/S on 10 of the 13 factors compared between the two stocks.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

CELLECT BIOTECH/S Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.